BBNX
Beta Bionics, Inc.
$9.65
-8.10%
2026-05-08
About Beta Bionics, Inc.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
Key Fundamentals
Forward P/E
-4.30
EPS (TTM)
$-1.37
ROE
-22.7%
Revenue Growth (YoY)
56.6%
Profit Margin
-60.3%
Debt/Equity
2.55
Price/Book
1.69
Market Cap
$457.6M
Avg Volume (10D)
694K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$14.74
60D Low
$8.80
Avg Volume
1.1M
Latest Close
$9.65
Get breakout alerts for BBNX
Sign up for Breakout Scanner to receive daily notifications when BBNX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Beta Bionics, Inc. (BBNX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors BBNX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. BBNX operates in the Healthcare sector within the Medical Devices industry. Data is provided for informational purposes only and does not constitute financial advice.